Banu Iskender
Izmit, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Reprogramming-driven Proteomic Shifts Mirror Bladder Cancer Progression and Reveal Biomarker Candidates Across Disease Grades.
Journal: Cancer genomics & proteomics
Published: April 03, 2026
Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity.
Journal: Cancer genomics & proteomics
Published: November 20, 2025
Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
Journal: BMC cancer
Published: June 10, 2025
Current status in cancer cell reprogramming and its clinical implications.
Journal: Journal of cancer research and clinical oncology
Published: June 11, 2016
Long Term Exposure to Myrtucommulone-A Changes CD105 Expression and Differentiation Potential of Mesenchymal Stem Cells.
Journal: Tissue engineering and regenerative medicine
Published: February 19, 2016
Reprogramming bladder cancer cells for studying cancer initiation and progression.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: January 25, 2016
Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial-mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis.
Journal: Molecular and cellular biochemistry
Published: December 23, 2015
Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: November 13, 2015
Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice.
Journal: European cytokine network
Published: November 11, 2015
Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A.
Journal: Anti-cancer agents in medicinal chemistry
Published: September 21, 2015
The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: August 26, 2015
Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: July 15, 2015
Last Updated: 09/26/2026